Safety and Efficacy of Ranibizumab for Diabetic Macular Edema

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 24, 2014

Primary Completion Date

May 26, 2016

Study Completion Date

May 26, 2016

Conditions
Diabetic Macular Edema
Interventions
DRUG

Ranibizumab

Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.

DRUG

Ranibizumab

Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.

Trial Locations (2)

44124

Cole Eye Institute at Hillcrest Hospital, Mayfield Heights

44195

Cole Eye Institute, Cleveland Clinic, Cleveland

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Justis Ehlers

OTHER